Generalizability of the FOURIER trial to routine clinical care: Do trial participants represent patients in everyday practice?

[1]  B. Lewis,et al.  Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial , 2017, JAMA cardiology.

[2]  Matthew R. Reynolds,et al.  Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease , 2017, JAMA cardiology.

[3]  P. Heidenreich,et al.  Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk): Insights From the Department of Veterans Affairs. , 2017, Circulation.

[4]  T. Brown,et al.  Trends in Use of High-Intensity Statin Therapy After Myocardial Infarction, 2011 to 2014. , 2017, Journal of the American College of Cardiology.

[5]  J. Woodcock,et al.  Review of the Drug Trials Snapshots Program of the US Food and Drug Administration: Women in Cardiovascular Drug Trials , 2017, JAMA internal medicine.

[6]  A. Keech,et al.  Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease , 2017, The New England journal of medicine.

[7]  Andrew E Moran,et al.  Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease. , 2016, JAMA.

[8]  D. Waters,et al.  PCSK9 Inhibitors for Statin Intolerance? , 2016, JAMA.

[9]  B. Kissela,et al.  Validity of Claims-Based Stroke Algorithms in Contemporary Medicare Data: Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study Linked With Medicare Claims , 2014, Circulation. Cardiovascular quality and outcomes.

[10]  Nilay D Shah,et al.  Optum Labs: building a novel node in the learning health care system. , 2014, Health affairs.

[11]  Jin Fan,et al.  Billing code algorithms to identify cases of peripheral artery disease from administrative data , 2013, Journal of the American Medical Informatics Association : JAMIA.

[12]  Sebastian Schneeweiss,et al.  Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. , 2004, American heart journal.

[13]  Harlan M Krumholz,et al.  Representation of the elderly, women, and minorities in heart failure clinical trials. , 2002, Archives of internal medicine.

[14]  A. Khera,et al.  National Trends in Statin Use and Expenditures in the US Adult Population From 2002 to 2013: Insights From the Medical Expenditure Panel Survey , 2017, JAMA cardiology.

[15]  Jennifer G. Robinson,et al.  Reprint: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. , 2013, Journal of the American Pharmacists Association : JAPhA.

[16]  Eric Q. Wu,et al.  Comparative Effectiveness Without Head-to-Head Trials , 2012, PharmacoEconomics.